S. Steyn

发表

DMD054031 1975..1993

R. Obach, L. Di, B. Feng, 2013 .

Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.

R Scott Obach, George Chang, Ayman El-Kattan, 2010, Journal of medicinal chemistry.

Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase

S. Steyn, K. Castagnoli, G. Magnin, 2009, Neurotoxicity Research.

Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)

S. Steyn, M. Varma, A. El‐Kattan, 2015, Pharmaceutical Research.

Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.

R. Kurumbail, B. L. Kormos, M. Hayward, 2015, Journal of medicinal chemistry.

Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

T. Maurer, D. Scott, S. Steyn, 2016, Pharmaceutical Research.

Design and optimization of selective azaindole amide M1 positive allosteric modulators.

Gregory W. Kauffman, R. Obach, J. Edgerton, 2016, Bioorganic & medicinal chemistry letters.

Measurement of mitochondrial respiration in permeabilized murine neuroblastoma (N-2alpha) cells, a simple and rapid in situ assay to investigate mitochondrial toxins.

C. J. Van der Schyf, S. Steyn, L. Mienie, 2005, Journal of biochemical and biophysical methods.

Cytochrome-P450 Mediated Drug-Drug Interactions of Substrate Drugs: Assessing Clinical Risk Based on Molecular Properties and Extended Clearance Classification System.

S. Steyn, M. Varma, Stefanus J. Steyn, 2020, Molecular pharmaceutics.

Permeability Comparison between Hepatocyte and Low Efflux MDCKII Cell Monolayer

L. Di, Patrick E. Trapa, Y. Lai, 2014, The AAPS Journal.

Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.

R. Kurumbail, B. L. Kormos, P. Verhoest, 2014, Bioorganic & medicinal chemistry letters.

LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits

Matthew L. Maddess, A. Stepan, T. Sherer, 2020, Science Translational Medicine.

Lack of Effect of Sodium Benzoate at Reported Clinical Therapeutic Concentration on d-Alanine Metabolism in Dogs.

S. Steyn, M. Popiolek, B. Tierney, 2018, ACS chemical neuroscience.

LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficits

Matthew L. Maddess, A. Stepan, T. Sherer, 2018, bioRxiv.

Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.

Gregory W. Kauffman, J. Edgerton, S. Steyn, 2016, Journal of medicinal chemistry.

Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery.

D. Scott, S. Steyn, G. Chang, 2010, ACS medicinal chemistry letters.